OvaScience, Fred's, Weight Watchers Lead Wednesday's After-Hours Movers

Fred's Inc. (NASDAQ: FRED) picked up 12 percent after hours Wednesday after closing down 3 percent. Earlier Wednesday, the company said it will pay $66 million in cash and notes to acquire privately held Reeves-Sain Drug Store Inc.

Silver Spring Networks Inc. (NYSE: SSNI) shares gained nearly 12 percent in extended trading Wednesday, changing hands recently at $10.46. The company, which provides networking platforms to utilities, had closed down 8 percent earlier and didn't issue any news.

OvaScience Inc. (NASDAQ: OVAS) picked up 10 percent in late trading, changing hands at $54.83 recently. The shares had closed down 8 percent earlier after the company slated an investors' conference call on short notice for Friday concerning its Augment prospective treatment for infertility.

Chimerix Inc. (NASDAQ: CMRX) gained 10 percent in late trading, to $38.76. Its Chief Development Officer, Michael D. Rogers, acquired shares using his corporate-issued stock options, according to a filing Wednesday.

Relypsa Inc. (NASDAQ: RLYP) gained 10 percent after hours to $37.29. At Wednesday's closing, the shares were off 15 percent in the past five trading days.

Lannett Co. (NYSE: LCI) picked up 8 percent after hours to $69.75, after closing down more than 7 percent. The generic drug manufacturer didn't issue any news, but hit a 52-week high Tuesday.

Weight Watchers International Inc. (NYSE: WTW) gained more than 6 percent, after losing 6 percent in the regular session. The company didn't issue any reasons.

Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) fell 7 percent to $15.60, extending earlier losses. After the bell, the company said insiders will make a public offering.

Verint Systems Inc. (NASDAQ: VRNT) lost more than 4 percent after hours, trading recently at $56. The data analytics company reduced its guidance after the bell.

TETRA Technologies Inc. (NYSE: TTI) was up nearly 6 percent, after closing up by a similar percentage on no news.

See more from Benzinga

© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement